|
Orthologous residues
|
|
MYO5A (human): S1652‑p, MYO5A (mouse): S1650‑p, MYO5A (rat): S1625‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
immunoprecipitation, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
3T3-L1 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
Akt2 (mouse)
|
transfection of dominant-negative enzyme, activation of upstream enzyme, siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
insulin
|
|
|
|
increase
|
|
|
|
insulin
|
Akt1 (human)
|
|
inhibit treatment-induced increase
|
dominant negative Akt
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
ACTN1 (mouse)
|
|
Induces
|
molecular association, regulation
|
|
electrophoretic visualization, in vitro
|
|